Skip to main content

Advertisement

Table 3 Mixed Model Analysis by Treatment, Age, and Treatment by Age for Predose and Postdose Time Points*

From: Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day

Time Point (hr) Mixed Model Statistical Analysis SKAMP-D SKAMP-A SKAMP-Total SKAMP-QoL PERMP-A PERMP-C
   F Value P Value F Value P Value F Value P Value F Value P Value F Value P Value F Value P Value
-0.5 Treatment 3.69 .0574 10.88 .0013 48.67 <.0001 133.44 <.0001 34.98 <.0001 37.63 <.0001
  Age 8.65 .0040 3.55 .0623 5.76 .0181 0.95 .3307 1.49 .2251 1.60 .2080
  Treatment by age 0.10 .7574 0.72 .3971 0.31 .5771 0.02 .9027 0.20 .6580 0.17 .6793
1.5 Treatment 27.82 <.0001 19.41 <.0001 42.98 <.0001 2.92 .0903 18.95 <.0001 30.00 <.0001
  Age 6.83 .0102 6.63 .0113 6.93 .0097 0.03 .8716 0.59 .4430 0.54 .4627
  Treatment by age 2.38 .1255 1.91 .1693 2.32 .1307 0.09 .7625 0.49 .4876 0.02 .8854
2.5 Treatment 121.66 <.0001 79.31 <.0001 204.35 <.0001 61.19 <.0001 94.10 <.0001 103.60 <.0001
  Age 7.25 .0082 3.70 .0571 7.99 .0056 2.49 .1172 0.14 .7066 0.23 .6303
  Treatment by age 5.99 .0159 0.01 .9253 1.93 .1672 0.02 .8971 1.74 .1902 1.27 .2619
5.0 Treatment 126.22 <.0001 79.64 <.0001 213.18 <.0001 89.58 <.0001 117.59 <.0001 122.97 <.0001
  Age 5.20 .0245 6.59 .0116 8.64 .0040 2.49 .1173 0.04 .8480 0.07 .7974
  Treatment by age 5.57 .0201 0.49 .4865 4.54 .0353 2.72 .1018 4.41 .0379 4.25 .0415
7.5 Treatment 109.78 <.0001 98.23 <.0001 215.28 <.0001 76.54 <.0001 134.00 <.0001 137.53 <.0001
  Age 5.27 .0236 6.93 .0097 7.27 .0081 0.00 .9885 0.21 .6473 0.35 .5544
  Treatment by age 0.12 .7342 6.55 .0118 2.06 .1543 0.06 .8090 1.55 .2159 1.38 .2418
10 Treatment 72.09 <.0001 68.52 <.0001 150.65 <.0001 32.26 <.0001 108.63 <.0001 115.45 <.0001
  Age 3.26 .0736 11.15 .0011 7.22 .0083 0.23 .6300 0.60 .4393 0.64 .4271
  Treatment by age 0.83 .3636 0.04 .8433 0.05 .8172 1.00 .3186 0.20 .6556 0.05 .8202
12 Treatment 34.82 <.0001 44.84 <.0001 100.99 <.0001 30.71 <.0001 74.62 <.0001 81.57 <.0001
  Age 5.34 .0227 9.44 .0027 12.67 .0006 3.97 .0487 0.13 .7163 0.06 .8065
  Treatment by age 0.42 .5170 0.06 .8007 0.00 .9549 1.06 .3058 0.27 .6020 0.13 .7158
13 Treatment 8.29 .0048 34.69 <.0001 38.63 <.0001 10.26 .0018 67.42 <.0001 68.29 <.0001
  Age 5.56 .0201 7.40 .0076 9.48 .0026 0.34 .5637 0.03 .8639 0.09 .7587
  Treatment by age 0.01 .9293 0.45 .5018 0.45 .5051 2.15 .1458 0.02 .8820 0.02 .8913
  1. LDX: lisdexamfetamine dimesylate; PERMP: Permanent Product Measure of Performance; PERMP-A: PERMP-Attempted; PERMP-C: PERMP-Correct; SKAMP: Swanson, Kotkin, Agler, M-Flynn, and Pelham; SKAMP-A: SKAMP-Attention; SKAMP-D: SKAMP-Deportment.
  2. *Degrees of freedom (df) = 110 for all analyses except the 7.5-hour postdose time point where df = 109 for all analyses.